当前位置: 首页 >> 检索结果
1. Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS).
作者: Maarten Te Groen.;Anouk M Wijnands.;Nathan den Broeder.;Dirk J de Jong.;Willemijn A van Dop.;Marjolijn Duijvestein.;Herma H Fidder.;Fiona van Schaik.;Meike M C Hirdes.;Andrea E van der Meulen-de Jong.;P W Jeroen Maljaars.;Philip W Voorneveld.;K H Nanne de Boer.;Charlotte P Peters.;Bas Oldenburg.;Frank Hoentjen.; .
来源: Gut. 2025年74卷4期547-556页
It remains unclear if the increased colorectal neoplasia detection rate in inflammatory bowel disease (IBD) by high-definition (HD) dye-based chromoendoscopy compared with HD white-light endoscopy is due to enhanced contrast or increased inspection times. Longer withdrawal times may yield similar neoplasia detection rates as found by HD chromoendoscopy.
2. Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
作者: Javier P Gisbert.;María G Donday.;Sabino Riestra.;Alfredo J Lucendo.;José-Manuel Benítez.;Mercè Navarro-Llavat.;Jesús Barrio.;Víctor J Morales-Alvarado.;Montserrat Rivero.;David Busquets.;Eduardo Leo Carnerero.;Olga Merino.;Óscar Nantes Castillejo.;Pablo Navarro.;Manuel Van Domselaar.;Ana Gutiérrez.;Inmaculada Alonso-Abreu.;Rafael Mejuto.;Luis Fernández-Salazar.;Marisa Iborra.;María Dolores Martín-Arranz.;Juan Ramón Pineda.;Manuela Josefa Sampedro.;Katja Serra Nilsson.;Abdel Bouhmidi.;Lissette Batista.;Carmen Muñoz Villafranca.;Iago Rodríguez-Lago.;Daniel Ceballos.;Iván Guerra.;Miriam Mañosa.;Ignacio Marín Jiménez.;Emilio Torrella.;Maribel Vera Mendoza.;María José Casanova.;Ruth de Francisco.;Laura Arias-González.;Sandra Marín Pedrosa.;Orlando García-Bosch.;Francisco Javier García-Alonso.;Pedro Delgado-Guillena.;María José García.;Leyanira Torrealba.;Andrea Núñez-Ortiz.;Miren Vicuña Arregui.;Marta Maia Bosca-Watts.;Isabel Blázquez.;Diana Acosta.;Ana Garre.;Montse Baldán.;Concepción Martínez.;Manuel Barreiro-de Acosta.;Eugeni Domènech.;Maria Esteve.;Valle García-Sánchez.;Pilar Nos.;Julián Panés.;María Chaparro.; .
来源: Gut. 2025年74卷3期387-396页
Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it.
3. Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
作者: Aurelien Amiot.;Philippe Seksik.;Antoine Meyer.;Carmen Stefanescu.;Pauline Wils.;Romain Altwegg.;Lucine Vuitton.;Laurianne Plastaras.;Adrien Nicolau.;Bruno Pereira.;Nicoals Duveau.;David Laharie.;Bassirou Mboup.;Medina Boualit.;Matthieu Allez.;Sylvie Rajca.;Elise Chanteloup.;Guillaume Bouguen.;Thomas Bazin.;Felix Goutorbe.;Nicolas Richard.;Driffa Moussata.;Eric Vicaut.;Laurent Peyrin-Biroulet.
来源: Gut. 2025年74卷2期197-205页
It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) episode responding to intravenous steroids.
4. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases.
作者: Yuanfang Li.;Yongqiang Zheng.;Jiaqian Huang.;Run-Cong Nie.;Qi-Nian Wu.;Zhijun Zuo.;Shuqiang Yuan.;Kai Yu.;Cheng-Cai Liang.;Yi-Qian Pan.;Bai-Wei Zhao.;Yuhong Xu.;Qihua Zhang.;Yashang Zheng.;Junquan Chen.;Zhao-Lei Zeng.;Wei Wei.;Ze-Xian Liu.;Rui-Hua Xu.;Hui-Yan Luo.
来源: Gut. 2025年74卷3期350-363页
Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer peritoneal metastasis (GCPM) have a poor prognosis and respond poorly to conventional treatments. Recently, immune checkpoint blockade (ICB) has demonstrated favourable efficacy in the treatment of GCPM. Stratification of best responders and elucidation of resistance mechanisms of ICB therapies are highly important and remain major clinical challenges.
5. Combined MRI, high-resolution manometry and a randomised trial of bisacodyl versus hyoscine show the significance of an enlarged colon in constipation: the RECLAIM study.
作者: Victoria Wilkinson-Smith.;Mark Scott.;Alex Menys.;Lukasz Wiklendt.;Luca Marciani.;David Atkinson.;Stefano Sansone.;Ausra Zdanaviciene.;Carol Coupland.;Charles H Knowles.;Philip Dinning.;Stuart A Taylor.;Penny Gowland.;Caroline Louise Hoad.;Maura Corsetti.;Robin C Spiller.
来源: Gut. 2024年74卷1期35-44页
Colonic motility in constipation can be assessed non-invasively using MRI.
6. Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial.
作者: Anke M Onnekink.;Myrte Gorris.;Noor Lh Bekkali.;Philip Bos.;Paul Didden.;J Enrique Dominguez-Muñoz.;Pieter Friederich.;Emo E van Halsema.;Wouter L Hazen.;Nadine C van Huijgevoort.;Akin Inderson.;Maarten Ajm Jacobs.;Jan J Koornstra.;Sjoerd Kuiken.;Bob Ch Scheffer.;Hilbert Sloterdijk.;Ellert J van Soest.;Niels G Venneman.;Rogier P Voermans.;Thomas R de Wijkerslooth.;Janneke Wonders.;Roeland Zoutendijk.;Serge Jlb Zweers.;Paul Fockens.;Robert C Verdonk.;Roy L J van Wanrooij.;Jeanin E Van Hooft.; .
来源: Gut. 2025年74卷2期246-254页
Endoscopic retrograde cholangiopancreatography (ERCP) with fully covered self-expandable metal stent (FCSEMS) placement is the preferred approach for biliary drainage in patients with suspected distal malignant biliary obstruction (MBO). However, FCSEMS placement is associated with a high risk of post-ERCP pancreatitis (PEP). Endoscopic sphincterotomy prior to FCSEMS placement may reduce PEP risk.
7. Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.
作者: David Z Pan.;Cameron M Soulette.;Abhishek Aggarwal.;Dong Han.;Nicholas van Buuren.;Peiwen Wu.;Becket Feierbach.;Jaw-Town Lin.;Cheng-Hao Tseng.;Chi-Yi Chen.;Bryan Downie.;Hongmei Mo.;Lauri Diehl.;Li Li.;Simon P Fletcher.;Scott Balsitis.;Ricardo Ramirez.;Vithika Suri.;Yao-Chun Hsu.
来源: Gut. 2025年74卷4期628-638页
The impact of nucleos(t)ide analogues on intrahepatic viral burden and immune microenvironment in patients with chronic hepatitis B (CHB) is not clear.
8. Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989.
作者: Lung Yi Mak.;Christine I Wooddell.;Oliver Lenz.;Thomas Schluep.;James Hamilton.;Heather L Davis.;Xianhua Mao.;Wai-Kay Seto.;Michael Biermer.;Man-Fung Yuen.
来源: Gut. 2025年74卷3期440-450页
RNA interference has been extensively explored in patients with chronic hepatitis B (CHB) infection. We aimed to characterise the long-term efficacy of small interfering RNA (siRNA) on hepatitis B surface antigen (HBsAg) suppression.
9. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
作者: Nicolas Pierre.;Vân Anh Huynh-Thu.;Dominique Baiwir.;Gabriel Mazzucchelli.;Maximilien Fléron.;Lisette Trzpiot.;Gauthier Eppe.;Edwin De Pauw.;David Laharie.;Jack Satsangi.;Peter Bossuyt.;Lucine Vuitton.;Sophie Vieujean.;Jean-Frédéric Colombel.;Marie-Alice Meuwis.;Edouard Louis.; .
来源: Gut. 2024年73卷12期1965-1973页
In patients with Crohn's disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (≤6 months) and mid/long-term relapse (>6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy).
10. Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
作者: Harsh Vardhan Tevethia.;Apurva Pande.;Rajan Vijayaraghavan.;Guresh Kumar.;Shiv Kumar Sarin.
来源: Gut. 2024年73卷11期1844-1853页
Beta-blockers and endoscopic variceal band ligation (VBL) have been preferred therapies for primary prophylaxis of variceal bleeding. However, the choice of therapy in patients with advanced liver disease with high-risk varices is not clear. A comparison of these therapies alone or in combination to prevent the first variceal bleed in advanced cirrhosis patients was carried out.
11. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
作者: Andrea Vecchi.;Marzia Rossi.;Camilla Tiezzi.;Paola Fisicaro.;Sara Doselli.;Elena Adelina Gabor.;Amalia Penna.;Ilaria Montali.;Camilla Ceccatelli Berti.;Valentina Reverberi.;Anna Montali.;Simon P Fletcher.;Elisabetta Degasperi.;Dana Sambarino.;Diletta Laccabue.;Floriana Facchetti.;Simona Schivazappa.;Elisabetta Loggi.;Barbara Coco.;Daniela Cavallone.;Elena Rosselli Del Turco.;Marco Massari.;Giuseppe Pedrazzi.;Gabriele Missale.;Gabriella Verucchi.;Pietro Andreone.;Maurizia Rossana Brunetto.;Pietro Lampertico.;Carlo Ferrari.;Carolina Boni.
来源: Gut. 2024年73卷10期1737-1748页
Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-α on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-α for a tailored application of IFN-α add-on.
12. Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial.
作者: Timothy O'Sullivan.;Oliver Cronin.;W Arnout van Hattem.;Francesco Vito Mandarino.;Julia L Gauci.;Clarence Kerrison.;Anthony Whitfield.;Sunil Gupta.;Eric Lee.;Stephen J Williams.;Nicholas Burgess.;Michael J Bourke.
来源: Gut. 2024年73卷11期1823-1830页
Conventional hot snare endoscopic mucosal resection (H-EMR) is effective for the management of large (≥20 mm) non-pedunculated colon polyps (LNPCPs) however, electrocautery-related complications may incur significant morbidity. With a superior safety profile, cold snare EMR (C-EMR) of LNPCPs is an attractive alternative however evidence is lacking. We conducted a randomised trial to compare the efficacy and safety of C-EMR to H-EMR.
13. Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy.
作者: Wen Gao.;Jianxiang Liu.;Xiaolei Wang.;Jingwen Li.;Xuezhi Zhang.;Hui Ye.;Jiang Li.;Xinhong Dong.;Binbin Liu.;Chi Wang.;Ying Xu.;Guigen Teng.;Yuling Tian.;Jinpei Dong.;Chaoyi Ge.;Hong Cheng.
来源: Gut. 2024年73卷9期1414-1420页
This study aimed to evaluate the efficacy and safety of vonoprazan and tetracycline (VT) dual therapy as first-line treatment for Helicobacter pylori infection in patients with penicillin allergy.
14. Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial.
作者: Amit G Singal.;Manasa Narasimman.;Darine Daher.;Sruthi Yekkaluri.;Yan Liu.;MinJae Lee.;Vanessa Cerda.;Aisha Khan.;Karim Seif El Dahan.;Jennifer Kramer.;Purva Gopal.;Caitlin Murphy.;Ruben Hernaez.
来源: Gut. 2024年73卷12期2037-2044页
Hepatocellular carcinoma (HCC) is plagued by failures across the cancer care continuum, leading to frequent late-stage diagnoses and high mortality. We evaluated the effectiveness of mailed outreach invitations plus patient navigation to promote HCC screening process completion in patients with cirrhosis.
15. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis.
作者: Jinxia Liu.;Jane MacNaughtan.;Annarein J C Kerbert.;Theo Portlock.;Javier Martínez Gonzalez.;Yi Jin.;Frederick Clasen.;Abeba Habtesion.;Huoyan Ji.;Qin Jin.;Alexandra Phillips.;Francesco De Chiara.;Ganesh Ingavle.;Cesar Jimenez.;Giacomo Zaccherini.;Katherine Husi.;Miguel Angel Rodriguez Gandia.;Paul Cordero.;Junpei Soeda.;Lynda McConaghy.;Jude Oben.;Karen Church.;Jia V Li.;Haifeng Wu.;Aarti Jalan.;Pere Gines.;Elsa Solà.;Simon Eaton.;Carrie Morgan.;Michal Kowalski.;Daniel Green.;Amir Gander.;Lindsey A Edwards.;I Jane Cox.;Helena Cortez-Pinto.;Thomas Avery.;Reiner Wiest.;Francois Durand.;Paolo Caraceni.;Roberto Elosua.;Joan Vila.;Marco Pavesi.;Vicente Arroyo.;Nathan Davies.;Rajeshwar P Mookerjee.;Victor Vargas.;Susan Sandeman.;Gautam Mehta.;Saeed Shoaie.;Julian Marchesi.;Agustín Albillos.;Fausto Andreola.;Rajiv Jalan.
来源: Gut. 2024年73卷7期1183-1198页
Targeting bacterial translocation in cirrhosis is limited to antibiotics with risk of antimicrobial resistance. This study explored the therapeutic potential of a non-absorbable, gut-restricted, engineered carbon bead adsorbent, Yaq-001 in models of cirrhosis and acute-on-chronic liver failure (ACLF) and, its safety and tolerability in a clinical trial in cirrhosis.
16. Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
作者: Ruben Y Gabriëls.;Anne M van der Waaij.;Matthijs D Linssen.;Michael Dobosz.;Pia Volkmer.;Sumreen Jalal.;Dominic Robinson.;Marcela A Hermoso.;Marjolijn N Lub-de Hooge.;Eleonora A M Festen.;Gursah Kats-Ugurlu.;Gerard Dijkstra.;Wouter B Nagengast.
来源: Gut. 2024年73卷9期1454-1463页
Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby providing individualised treatment strategies. We aimed to visualise the macroscopic and microscopic distribution of intravenous injected fluorescently labelled vedolizumab, vedo-800CW, and identify its target cells using fluorescence molecular imaging (FMI).
17. Faecal microbial transfer and complex carbohydrates mediate protection against COPD.
作者: Kurtis F Budden.;Shakti D Shukla.;Kate L Bowerman.;Annalicia Vaughan.;Shaan L Gellatly.;David L A Wood.;Nancy Lachner.;Sobia Idrees.;Saima Firdous Rehman.;Alen Faiz.;Vyoma K Patel.;Chantal Donovan.;Charlotte A Alemao.;Sj Shen.;Nadia Amorim.;Rajib Majumder.;Kanth S Vanka.;Jazz Mason.;Tatt Jhong Haw.;Bree Tillet.;Michael Fricker.;Simon Keely.;Nicole Hansbro.;Gabrielle T Belz.;Jay Horvat.;Thomas Ashhurst.;Caryn van Vreden.;Helen McGuire.;Barbara Fazekas de St Groth.;Nicholas J C King.;Ben Crossett.;Stuart J Cordwell.;Lorenzo Bonaguro.;Joachim L Schultze.;Emma E Hamilton-Williams.;Elizabeth Mann.;Samuel C Forster.;Matthew A Cooper.;Leopoldo N Segal.;Sanjay H Chotirmall.;Peter Collins.;Rayleen Bowman.;Kwun M Fong.;Ian A Yang.;Peter A B Wark.;Paul G Dennis.;Philip Hugenholtz.;Philip M Hansbro.
来源: Gut. 2024年73卷5期751-769页
Chronic obstructive pulmonary disease (COPD) is a major cause of global illness and death, most commonly caused by cigarette smoke. The mechanisms of pathogenesis remain poorly understood, limiting the development of effective therapies. The gastrointestinal microbiome has been implicated in chronic lung diseases via the gut-lung axis, but its role is unclear.
18. Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study.
作者: Xue Xiao.;Xian Zhang.;Jin Wang.;Yuqiang Liu.;Hailin Yan.;Xiaocun Xing.;Jinlin Yang.
来源: Gut. 2024年73卷7期1098-1109页
The mechanism by which proton pump inhibitors (PPIs) alter gut microbiota remains to be elucidated. We aimed to learn whether PPI induced gut microbiota alterations by promoting oral microbial translocation.
19. Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study).
作者: Iain Robert Louis Kean.;John A Clark.;Zhenguang Zhang.;Esther Daubney.;Deborah White.;Paloma Ferrando-Vivas.;Gema Milla.;Brian Cuthbertson.;John Pappachan.;Nigel Klein.;Paul Mouncey.;Kathy Rowan.;John Myburgh.;Theodore Gouliouris.;Stephen Baker.;Julian Parkhill.;Nazima Pathan.; Arctic Research Team.
来源: Gut. 2024年73卷6期910-921页
Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resistance (AMR) gene profiles in critically ill children treated with SDD-enhanced infection control compared with conventional infection control.
20. Standardised training for endoscopic mucosal resection of large non-pedunculated colorectal polyps to reduce recurrence (*STAR-LNPCP study): a multicentre cluster randomised trial.
作者: Lonne W T Meulen.;Roel M M Bogie.;Peter D Siersema.;Bjorn Winkens.;Marije S Vlug.;Frank H J Wolfhagen.;Martine Baven-Pronk.;Michael van der Voorn.;Matthijs P Schwartz.;Lauran Vogelaar.;Wouter H de Vos Tot Nederveen Cappel.;Tom C J Seerden.;Wouter L Hazen.;Ruud W M Schrauwen.;Lorenza Alvarez Herrero.;Ramon-Michel M Schreuder.;Annick B van Nunen.;Esther Stoop.;Gijs J de Bruin.;Philip Bos.;Willem A Marsman.;Edith Kuiper.;Marc de Bièvre.;Yasser A Alderlieste.;Robert Roomer.;John Groen.;Marloes Bargeman.;Monique E van Leerdam.;Linda Roberts-Bos.;Femke Boersma.;Karsten Thurnau.;Roland S de Vries.;Jos M Ramaker.;Frank P Vleggaar.;Rogier J de Ridder.;María Pellisé.;Michael J Bourke.;Ad A M Masclee.;Leon M G Moons.
来源: Gut. 2024年73卷5期741-750页
Endoscopic mucosal resection (EMR) is the preferred treatment for non-invasive large (≥20 mm) non-pedunculated colorectal polyps (LNPCPs) but is associated with an early recurrence rate of up to 30%. We evaluated whether standardised EMR training could reduce recurrence rates in Dutch community hospitals.
|